The diagnostic and therapeutic management of leptomeningeal carcinomatosis, Ann Oncol, vol.15, pp.285-91, 2004. ,
Leptomeningeal metastases in the MRI era, Neurology, vol.74, pp.1449-54, 2010. ,
Intrathecal chemotherapy for treatment of leptomeningeal dissemination of metastatic tumours, Lancet Oncol, vol.11, issue.10, pp.70034-70040, 2010. ,
Carcinomatous meningitis: Leptomeningeal metastases in solid tumors, Surg Neurol Int, vol.4, pp.265-88, 2013. ,
Leptomeningeal metastasis: clinical experience of 519 cases, Eur J Cancer, vol.56, pp.107-121, 2016. ,
Epidermal growth factor receptor tyrosine kinase inhibitors for non-small-cell lung cancer patients with leptomeningeal carcinomatosis, J Thorac Oncol, vol.10, pp.1754-61, 2015. ,
Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: okayama lung cancer study group, Lung Cancer, vol.77, pp.134-143, 2012. ,
Prolonged survival of patients with non-small-cell lung cancer with leptomeningeal carcinomatosis in the modern treatment era, Clin Lung Cancer, vol.15, pp.202-208, 2014. ,
Therapy of leptomeningeal metastasis in solid tumors, Cancer Treat Rev, vol.43, pp.83-91, 2016. ,
Leptomeningeal metastasis: a response assessment in neuro-oncology critical review of endpoints and response criteria of published randomized clinical trials, Neuro-Oncology, vol.16, pp.1176-85, 2014. ,
Leptomeningeal metastasis, Curr Opin Oncol, vol.22, pp.627-662, 2010. ,
Intracranial leptomeningeal metastases: comparison of depiction at FLAIR and contrast-enhanced MR imaging, Radiology, vol.217, pp.50-53, 2000. ,
, Central Nervous System Cancers
Novel method for the detection and quantification of malignant cells in the CSF of patients with leptomeningeal metastasis of lung cancer, Oncol Lett, vol.11, pp.619-642, 2016. ,
Rare cell capture technology for the diagnosis of leptomeningeal metastasis in solid tumors, Neurology, vol.80, pp.1598-605, 2013. ,
Detection of epithelial growth factor receptor mutations in cerebrospinal fluid from patients with lung adenocarcinoma suspected of neoplastic meningitis, J Thorac Oncol, vol.6, pp.1215-1235, 2011. ,
Diagnostic significance of cerebrospinal fluid EGFR mutation analysis for leptomeningeal metastasis in non-small-cell lung cancer patients harboring an active EGFR mutation following gefitinib therapy failure, Respir Investig, vol.54, pp.14-23, 2016. ,
A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis, J Clin Oncol, vol.5, pp.1655-62, 1987. ,
Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group, J Clin Oncol, vol.11, pp.561-570, 1993. ,
Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis, J Clin Oncol, vol.17, pp.3110-3116, 1999. ,
A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors, Clin Cancer Res, vol.5, pp.3394-402, 1999. ,
The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study, Eur J Cancer, vol.40, pp.2726-2759, 2004. ,
Route of intracerebrospinal fluid chemotherapy administration and efficacy of therapy in neoplastic meningitis, Cancer, vol.116, pp.1947-52, 2010. ,
Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy, J Thorac Oncol, vol.7, pp.382-387, 2012. ,
Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era, Lung Cancer, vol.76, pp.387-92, 2012. ,
Intrathecal chemotherapy as a treatment for leptomeningeal metastasis of non-small cell lung cancer: a pooled analysis, Oncol Lett, vol.12, pp.1301-1315, 2016. ,
Pemetrexed plus platinum as the first-line treatment option for advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials, PLoS ONE, vol.7, 2012. ,
Plasma and cerebrospinal fluid pharmacokinetics of pemetrexed after intravenous administration in non-human primates, Cancer Chemother Pharmacol, vol.59, pp.461-467, 2007. ,
Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01), Ann Oncol, vol.22, pp.2466-70, 2011. ,
Vascular endothelial growth factor (VEGF) in leptomeningeal metastasis: diagnostic and prognostic value, Br J Cancer, vol.91, pp.219-243, 2004. ,
Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma, J Neurooncol, vol.94, pp.229-263, 2009. ,
Bevacizumab prevents brain metastases formation in lung adenocarcinoma, Mol Cancer Ther, vol.15, pp.702-712, 2016. ,
A pilot study of bevacizumab combined with etoposide and cisplatin in breast cancer patients with leptomeningeal carcinomatosis, BMC Cancer, vol.15, p.299, 2015. ,
Outcome after whole brain radiotherapy alone in intracranial leptomeningeal carcinomatosis from solid tumors, Strahlenther Onkol, vol.188, pp.148-53, 2012. ,
Concurrent radiotherapy and intrathecal methotrexate for treating leptomeningeal metastasis from solid tumors with adverse prognostic factors: a prospective and single-arm study, Int J Cancer, vol.139, pp.1864-72, 2016. ,
Biomarkers France contributors, Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT), Lancet, vol.387, pp.1415-1441, 2016. ,
Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Intergroup (IFCT), The Lancet, 2016. ,
Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping, Cancer Discov, vol.5, pp.842-851, 2015. ,
Crizotinib in ROS1-rearranged non-small-cell lung cancer, N Engl J Med, vol.371, pp.1963-71, 2014. ,
Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs, JAMA, vol.311, 1998. ,
BRAIN: a phase trial comparing WBI and chemotherapy with Icotinib in NSCLC with brain metastases harboring EGFR mutations (CTONG 1201), J Clin Oncol, vol.34, 2016. ,
Common EGFR-mutated subgroups (Del19/L858R) in advanced non-small-cell lung cancer: chasing better outcomes with tyrosinekinase inhibitors, Future Oncol, vol.2015, pp.1-13 ,
Frequent EGFR mutations in brain metastases of lung adenocarcinoma, Int J Cancer, vol.119, pp.1491-1495, 2006. ,
Frequency of brain metastases in non-small-cell lung cancer, and their association with epidermal growth factor receptor mutations, Int J Clin Oncol, vol.20, pp.674-683, 2015. ,
Leptomeningeal metastases in patients with NSCLC with EGFR mutations, J Thorac Oncol, vol.11, pp.1962-1971, 2016. ,
Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: a retrospective cohort analysis, Lung Cancer, vol.89, pp.255-61, 2015. ,
Impact of EGFR tyrosine kinase inhibitors versus chemotherapy on the development of leptomeningeal metastasis in never smokers with advanced adenocarcinoma of the lung, J Neurooncol, vol.115, pp.95-101, 2013. ,
High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib, Cancer, vol.103, pp.2344-2352, 2005. ,
Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with nonsmall-cell lung cancer, Cancer, vol.116, pp.1336-1379, 2010. ,
Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor-mutant nonsmall cell lung cancer metastatic to the brain, Clin Cancer Res, vol.18, pp.938-982, 2012. ,
Cerebrospinal fluid concentrations of gefitinib in patients with lung adenocarcinoma, Clin Lung Cancer, vol.14, pp.188-93, 2013. ,
Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib, J Clin Oncol, vol.24, pp.4517-4537, 2006. ,
Carcinomatous meningitis in non-small-cell lung cancer: response to high-dose erlotinib, J Clin Oncol, vol.27, pp.31-32, 2009. ,
High-dose erlotinib for refractory leptomeningeal metastases after failure of standarddose EGFR-TKIs, Cancer Chemother Pharmacol, vol.75, pp.1261-1267, 2015. ,
High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer, J Neurooncol, vol.99, pp.283-289, 2010. ,
A phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer, Oncotarget, vol.6, pp.4527-4563, 2015. ,
Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer, Neuro-Oncology, vol.13, pp.1364-1373, 2011. ,
Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer, Cancer Chemother Pharmacol, vol.70, pp.399-405, 2012. ,
Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lung cancer, J Thorac Oncol, vol.8, pp.1069-74, 2013. ,
Two cases of leptomeningeal metastases from lung adenocarcinoma which progressed during gefitinib therapy but responded to erlotinib, Int J Clin Oncol, vol.17, pp.155-164, 2012. ,
First-line afatinib versus chemotherapy in patients with non-small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases, J Thorac Oncol, vol.11, pp.380-90, 2016. ,
Afatinib Compassionate Use Consortium (ACUC), efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease, J Thorac Oncol, vol.10, pp.156-63, 2015. ,
Efficacy and Cerebrospinal Fluid Concentration of Afatinib in NSCLC Patients with EGFR Mutation Developing Leptomeningeal Carcinomatosis, J Thorac Oncol, 2016. ,
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors, Sci Transl Med, vol.3, 2011. ,
Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acidbased assay, Clin Cancer Res, vol.17, pp.1169-80, 2011. ,
Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers, Clin Cancer Res, vol.19, pp.2240-2247, 2013. ,
AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer, Cancer Discov, vol.4, pp.1046-61, 2014. ,
Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-Mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity, Clin Cancer Res, 2016. ,
High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with EGFR-mutant lung cancer cells, Oncotarget, vol.7, pp.3847-56, 2016. ,
Osimertinib activity in patients (pts) with leptomeningeal (LM) disease from non-small cell lung cancer (NSCLC): Updated results from BLOOM, a phase I study, ASCO. Meeting Abstr, vol.34, p.9002, 2016. ,
Spatiotemporal T790M Heterogeneity in Individual Patients with EGFR-Mutant Non-Small-Cell Lung Cancer after Acquired Resistance to EGFR-TKI, J Thorac Oncol, vol.10, pp.1553-1562, 2015. ,
Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced nonsquamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study, Lancet Oncol, vol.15, pp.1236-1280, 2014. ,
A phase II trial of erlotinib (E) and bevacizumab (B) _in patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutations with and without T790M mutation.Spanish Lung Cancer Group and the European Thoracic Oncology Platform BELIEF trial ,
Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001, J Thorac Oncol, vol.10, pp.486-91, 2015. ,
Demystifying brain penetration in central nervous system drug discovery. Miniperspective, J Med Chem, vol.56, pp.2-12, 2013. ,
AZD3759, an EGFR inhibitor with blood brain barrier (BBB) penetration for the treatment of non-small cell lung cancer (NSCLC) with brain metastasis (BM): Preclinical evidence and clinical cases, ASCO. Meeting Abstr, vol.33, p.8016, 2015. ,
Phase I study of AZD3759, a CNS penetrable EGFR inhibitor, for the treatment of non-smallcell lung cancer (NSCLC) with brain metastasis (BM) and leptomeningeal metastasis (LM), ASCO Meeting Abstr, vol.34, p.9003, 2016. ,
Biomarkers France contributors, Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT), Lancet, 2016. ,
The central nervous system as a sanctuary site in ALK-positive non-small-cell lung cancer, J Thorac Oncol, vol.8, pp.1570-1573, 2013. ,
First-line crizotinib versus chemotherapy in ALK-positive lung cancer, N Engl J Med, vol.371, pp.2167-77, 2014. ,
Crizotinib vs chemotherapy in ALK+ advanced non-small cell lung cancer (NSCLC): Final survival results from PROFILE 1007, ASCO Meeting Abst, vol.34, p.9066, 2016. ,
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer, N Engl J Med, vol.368, pp.2385-94, 2013. ,
Ceritinib in ALK-rearranged non-small-cell lung cancer, N Engl J Med, vol.370, pp.1189-97, 2014. ,
CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib, J Clin Oncol, vol.29, pp.443-448, 2011. ,
Clinical experience with crizotinib in patients with advanced ALK-rearranged nonsmall-cell lung cancer and brain metastases, J Clin Oncol, vol.33, pp.1881-1889, 2015. ,
Intracranial efficacy of crizotinib versus chemotherapy in patients with advanced ALK-positive non-small-cell lung cancer: results from PROFILE 1014, J Clin Oncol, 2016. ,
ALK inhibitor crizotinib combined with intrathecal methotrexate treatment for non-small cell lung cancer with leptomeningeal carcinomatosis, Lung Cancer, vol.76, pp.253-257, 2012. ,
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial, Lancet Oncol, vol.17, issue.15, pp.614-616, 2016. ,
Multicenter phase II study of whole-body and intracranial activity with ceritinib in patients with ALK-rearranged non-small-cell lung cancer previously treated with chemotherapy and crizotinib: results from ASCEND-2, J Clin Oncol, 2016. ,
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study, Lancet Oncol, vol.15, pp.70362-70368, 2014. ,
Alectinib (ALC) versus crizotinib (CRZ) in ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK+ NSCLC): primary results from the J-ALEX study, ASCO. Meeting Abst, vol.34, p.9008, 2016. ,
Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib, J Thorac Oncol, vol.10, pp.232-238, 2015. ,
Brigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory ALK+ nonsmall cell lung cancer (NSCLC): First report of efficacy and safety from a pivotal randomized phase (ph) 2 trial (ALTA), ASCO Meeting Abstr, vol.34, p.9007, 2016. ,
Brigatinib activity in patients with ALK+ NSCLC and intracranial CNS metastases in two clinical trials, J Clin Oncol, vol.34, 2016. ,
, , vol.06
), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALKresistant mutations, J Med Chem, vol.15, pp.4720-4764, 2014. ,
PF-06463922, an ALK/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models, Cancer Cell, vol.28, pp.70-81, 2015. ,
Safety and efficacy of lorlatinib (PF-06463922) from the dose-escalation component of a study in patients with advanced ALK+ or ROS1+ non-small cell lung cancer (NSCLC), ASCO Meeting Abst, vol.34, p.9009, 2016. ,
Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort, Ann Oncol, vol.27, pp.281-287, 2016. ,
Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis, Breast Cancer Res Treat, vol.139, pp.13-22, 2013. ,
, J Clin Oncol, vol.18, pp.2349-51, 2000.
Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier, Anticancer Drugs, vol.18, pp.23-31, 2007. ,
Intrathecal Trastuzumab Treatment in Patients with Breast Cancer and Leptomeningeal Carcinomatosis, Cancer Res Treat, vol.48, pp.843-850, 2016. ,
BRAF alterations as therapeutic targets in non-small-cell lung cancer, J Thorac Oncol, vol.10, pp.1396-403, 2015. ,
Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations, N Engl J Med, vol.373, pp.726-762, 2015. ,
Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial, Lancet Oncol, vol.17, issue.16, pp.30146-30148, 2016. ,
Vemurafenib in leptomeningeal carcinomatosis from melanoma: a case report of near-complete response and prolonged survival, Melanoma Res, vol.26, pp.312-317, 2016. ,
Prolonged survival of a patient with metastatic leptomeningeal melanoma treated with BRAF inhibition-based therapy: a case report, BMC Cancer, vol.15, p.400, 2015. ,
Vemurafenib for leptomeningeal melanomatosis, J Clin Oncol, vol.31, pp.173-174, 2013. ,
Cerebrospinal fluid concentrations of vemurafenib in patients treated for brain metastatic BRAF-V600 mutated melanoma, Melanoma Res, vol.25, pp.302-307, 2015. ,
Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer, N Engl J Med, vol.373, pp.123-158, 2015. ,
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer, N Engl J Med, 2015. ,
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial, Lancet, vol.387, issue.15, pp.1281-1288, 2016. ,
Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in advanced NSCLC, ESMO, vol.2016 ,
Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, openlabel, phase 2 trial, Lancet Oncol, vol.17, issue.16, pp.30053-30058, 2016. ,
Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases, Lung Cancer, vol.98, pp.114-121, 2016. ,
Leptomeningeal metastases: a RANO proposal for response criteria, Neuro-Oncology, 2016. ,